Arca Biopharma | ABIO - Ebitda


Arca Biopharma reported $-25.07M in EBITDA for its fiscal quarter ending in March of 2025.





Ebitda Change Date
Alterity Therapeutics Limited AUD -7.72M 2.99M Jun/2023
Amgen USD 3.86B 1.28B Mar/2026
Arca Biopharma USD -25.07M 5.23M Mar/2025
Biogen USD 649.7M 76.5M Mar/2026
Brainstorm Cell Therapeutics USD -3.04M 99K Mar/2025
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Capricor Therapeutics USD -27.23M 2.66M Jun/2025
Cipla INR 14.03B 4.48B Jun/2026
Clal Biotechnology ILS -5.3M 2.09M Dec/2022
Compugen USD -9.02M 1.12M Mar/2026
CSL USD 3.13B 1.17B Dec/2025
Cytokinetics USD -169.32M 19.48M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Grifols EUR 482.04M 7.04M Sep/2025
Laboratory Of America USD 767.7M 162.1M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Otsuka Holdings JPY 156.66B 56.89B Mar/2026
Pfizer USD 6.01B 18M Jun/2026
United Therapeutics USD 355M 11.1M Jun/2026